18/11/2021
The use of the adjuvant epirubicin for breast cancer in the United Kingdom has increased since initial data from the national epirubicin adjuvant trial (NEAT) were presented in 2003.1 Two women, aged 53 and 55 years, developed pain and restriction of movement of the arm due to venous sclerosis after...